ReviewF1000Research2019
Emerging therapies against infections with
Review in F1000Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 88 citations in OpenAlex.
- Proteomic Analysis of Three Independent Series of Sequential Cystic Fibrosis Strains in an International Pseudomonas aeruginosa Reference Panel Indicates Positive Selection in Late Infection Strains.MicrobiologyOpen · 2026Article
- Developing a Pseudomonas aeruginosa keratitis model in Swiss albino mice for clinical assessment.The Indian journal of medical research · 2025Article
- Detection of Genes Associated with Polymyxin and Antimicrobial Peptide Resistance in Isolates ofInternational journal of molecular sciences · 2025Article
- Alizarin, which reduces ExoS, attenuates inflammation by P. aeruginosa in H292 cells.Journal of microbiology (Seoul, Korea) · 2025Article
- Article
- Loop-Mediated Isothermal Amplification Coupled with Reverse Line Blot Hybridization for the Detection ofMicroorganisms · 2024Article
- Edible Medicinal Guava Fruit (Plants (Basel, Switzerland) · 2024Article
- Effect ofFrontiers in microbiology · 2024Article
- Review
- Development of an anti-Frontiers in cellular and infection microbiology · 2023Article
- Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-freeFrontiers in immunology · 2023Article
- Association of Multidrug Resistance Bacteria and Clinical Outcomes of Adult Patients with Sepsis in the Intensive Care Unit.Tropical medicine and infectious disease · 2022Article
- The current landscape of microRNAs (miRNAs) in bacterial pneumonia: opportunities and challenges.Cellular & molecular biology letters · 2022Review
- Article
- Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives.Biological reviews of the Cambridge Philosophical Society · 2022Review
- Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): antimicrobial-resistantEFSA journal. European Food Safety Authority · 2022Article
- Impact of Peptidoglycan Recycling Blockade and Expression of Horizontally Acquired β-Lactamases on Pseudomonas aeruginosa Virulence.Microbiology spectrum · 2022Article
- What Is New in the Anti-Frontiers in cellular and infection microbiology · 2022Review
- Treatment ofFrontiers in microbiology · 2022Review
- β-lactam Resistance inPathogens (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.